Incretin Atlas › Trials › HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600)
HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600)
HRS-4729 · obesity
Design
- Molecule(s)
- HRS-4729
- Population
- obesity
- Phase
- 1
- Participants
- 60
- Duration
- 12 weeks
- Registry
- NCT06762600
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 mg | obesity china | 12 | 60 | — | —−16.0 % vs −5.4 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- 12 mg · weight_unsp · press release
participants receiving multiple doses of 12 mg of HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-4729-phase-1-sad-mad-mad-part/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.